Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today announced that
the Company will report its financial results for the fourth quarter and
full-year 2015, on Wednesday, March 23, 2016 prior to a conference call
with the investment community scheduled at 8:00 a.m. ET.
Investors and the public are invited to access the live audio webcast
through the link below. Participants are encouraged to log-in and/or
dial-in fifteen minutes before the conference call begins. The webcast
replay is expected to be available on our investor website, http://ir.navidea.com,
approximately two to four hours after the live event.
Event:
Navidea Biopharmaceuticals Q4 and Year-End 2015 Financial Results
Conference Call
A webcast replay will be available on the Investor Relations
section of our website at http://ir.navidea.comfor 30 days.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical
company focused on the development and commercialization of precision
immunodiagnostic agents and immunotherapeutics. Navidea is developing
multiple precision-targeted products and platforms including Manocept™
and NAV4694 to help identify the sites and pathways of undetected
disease and enable better diagnostic accuracy, clinical decision-making,
targeted treatment and, ultimately, patient care. Lymphoseek®
(technetium Tc 99m tilmanocept) injection, Navidea's first commercial
product from the Manocept platform, was approved by the FDA in March
2013 and in Europe in November 2014. The development activities of the
Manocept immunotherapeutic platform will be conducted by Navidea in
conjunction with its subsidiary, Macrophage Therapeutics. Navidea's
strategy is to deliver superior growth and shareholder return by
bringing to market novel products and advancing the Company's pipeline
through global partnering and commercialization efforts. For more
information, please visit www.navidea.com.
